MedTrace Logo

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

NCT04561076 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-04-01

No results posted yet for this study

Summary

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Study to Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

Conditions

  • COVID 19

Interventions

DRUG

HLX70

Single-dose, intravenous infusion

OTHER

Placebo

Single-dose, intravenous infusion

Sponsors & Collaborators

  • Sanyou Biopharmaceuticals(Shanghai)Co., Ltd

    collaborator UNKNOWN

  • Shanghai ZJ Bio-Tech Co., Ltd

    collaborator UNKNOWN

  • Hengenix Biotech Inc

    lead INDUSTRY

Principal Investigators

  • Esther Yoon, MD · California Clinical Trials Medical Group (CCTMG) managed by Parexel

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-09
Primary Completion
2021-09-06
Completion
2021-09-18
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04561076 on ClinicalTrials.gov